EMA approves BF-200 ALA


Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its drug for the treatment of actinic keratosis. There was no recommendation for a restriction or temporal limitation of the approval. The substance, which Biofrontera had dubbed BF-200 ALA while in development, will now be marketed under the name Ameluz. The positive assessment report by the Committee for Medicinal Products for Human Use (CHMP) will now be forwarded to the European Commission for the formal conclusion of the process. Biofrontera anticipates final approval in December. After that, Ameluz can be commercialised in all 27 countries of the EU as well as Norway, Iceland and Liechtenstein, the company stated. Biofrontera began the application process in September of 2010.



Berlin - The World Health Summit is underway for its second visit to Berlin. The international conference is organised by the M8 Alliance of leading Academic Health Centers and Medical Universities and will go on until October...



Hanover - From October 5-7 the Biotechnica in Hanover attracted 9.500 visitors and 500 enterprises. This is the smallest edition for years. "In view of framework conditions currently affecting the biotech industry, this is a...



Tuebingen – Private German immunotherapy specialist immatics biotechnologies GmbH has raised EUR53.8 million in a Series C financing round With new funds that the company will use to push its lead cancer vaccine IMA901 into a...



Hanover – Addex Pharmaceuticals SA, Apeiron AG and and Galapagos Genomics NV have been chosen as finalists for this year’s European BIOTECHNICA Award. From Switzerland, Austria and Belgium respectively, one of the three firms...



Most rare diseases are hereditary but their exact cause often remains unclear. Researchers at the Max Planck used Next generation sequencing to unravel the causative gene behind the rare hereditary mental retardation disorder...



Cologne/Carlsbad – Protein expression provider CEVEC Pharmaceuticals has signed a co-exclusive worldwide licensing agreement with Life Technologies Corporation. Under the terms of the agreement, Life Technologies and CEVEC will...



Monheim – German supplier of specialty chemicals and nutritional ingredients Cognis has launched the first milk for reducing blood cholesterol on the Chinese market. The novel food, which is enriched with natural phytosterols,...

Displaying results 81 to 90 out of 454

< Previous 81-90 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • CO.DON2.97 EUR2.41%
  • MOLOGEN5.06 EUR0.80%
  • CYTOS1.28 CHF0.79%


  • MEDIGENE12.90 EUR-11.03%
  • 4SC1.18 EUR-5.60%
  • PAION2.37 EUR-5.58%


  • MEDIGENE12.90 EUR93.4%
  • 4SC1.18 EUR66.2%
  • FORMYCON31.00 EUR37.7%


  • CYTOS1.28 CHF-14.7%
  • MORPHOSYS60.74 EUR-12.8%
  • BB BIOTECH281.20 EUR-11.3%


  • SANTHERA99.75 CHF2709.9%
  • CYTOS1.28 CHF652.9%
  • FORMYCON31.00 EUR336.6%


  • MOLOGEN5.06 EUR-53.1%
  • PAION2.37 EUR-22.3%
  • BIOFRONTERA2.57 EUR-21.2%

No liability assumed, Date: 17.04.2015

Current issue

All issues